Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CDC42 | P60953 | 1/20 | 1.00 |
| ▸ | RAC1 | P63000 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL29360045 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL215236 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350675 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL28834409 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL616149 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29359528 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350704 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL30346195 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 614 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646404-A1 | PEPTIDE-HISTIDINAL CONJUGATES AS AN ANTI-MALARIAL AGENTS | Council of Scientific & Industrial Research (IN) | 2025-11-12 | — | — | EP | claimed |
| WO-2024147153-A1 | PEPTIDE-HISTIDINAL CONJUGATES AS AN ANTI-MALARIAL AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-07-11 | — | — | WO | claimed |
| CN-118290491-A | Copper nanocluster and preparation method thereof | 清华大学 | 2024-07-05 | — | — | CN | claimed |
| CN-117486929-A | Substituted alkyl germanium compound and modularized synthesis method thereof | 西安交通大学 | 2024-02-02 | — | — | CN | claimed |
| CN-113845417-B | Method for synthesizing (+/-) -naproxen by using continuous flow micro-channel reactor oxidation | 浙江车头制药股份有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-110573495-B | Trans-isomeric heterocyclic compounds and process for preparing same | 浙江医药股份有限公司新昌制药厂 | 2023-04-11 | — | — | CN | claimed |
| US-20220288022-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE THAT IS IN THE FORM OF A DISPERSED PHASE BASED ON AT LEAST ONE SHORT DIOL IN A CONTINUOUS FATTY PHASE AND COMPRISING AT LEAST ONE ANTI-INFLAMMATORY SUBSTANCE | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2022-09-15 | — | — | US | claimed |
| EP-4025182-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE THAT IS IN THE FORM OF A DISPERSED PHASE BASED ON AT LEAST ONE SHORT DIOL IN A CONTINUOUS FATTY PHASE AND COMPRISING AT LEAST ONE ANTI-INFLAMMATORY SUBSTANCE | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2022-07-13 | — | — | EP | claimed |
| CN-114502152-A | Pharmaceutical composition for topical use in the form of a dispersed phase based on at least one short-chain diol and comprising at least one anti-inflammatory substance in a continuous fatty phase | 化工产品开发公司SEPPIC | 2022-05-13 | — | — | CN | claimed |
| US-20220023208-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE ANTIINFLAMMATORY SUBSTANCE | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2022-01-27 | — | — | US | claimed |
| EP-0044984-B1 | PROCESS FOR THE OPTICAL RESOLUTION OF MIXTURES OF D- AND L-2-(6-METHOXY-2-NAPHTHYL)-PROPIONIC ACIDS, THE CINCHONIDINE SALT OF D-2-(6-METHOXY-2-NAPHTHYL)-PROPIONIC ACID AND THE PREPARATION THEREOF | ALFA FARMACEUTICI S.p.A. (IT) | 1984-03-07 | — | — | EP | claimed |
| EP-0095901-A1 | Process for the preparation of (d) 2-(d-methoxy-2-naphthyl) propionic acid and pharmaceutically acceptable salts thereof and new intermediates therefor | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1983-12-07 | — | — | EP | claimed |
| US-4417070-A | PREFERENTIAL CRYSTALLIZATION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1983-11-22 | — | — | US | claimed |
| US-4399284-A | Process for the optical resolution of mixtures of D- and L-2-(6-methoxy-2-naphthyl)-propionic acids | ALFA FARMACEUTICI S.P.A. (IT) | 1983-08-16 | — | — | US | claimed |
| EP-0022529-B1 | PROCESS FOR THE RESOLUTION OF D,L 2-(6-METHOXY-2-NAPHTHYL)PROPIONIC ACID; A MIXTURE OF THE SALTS OF THESE D AND L ACIDS; A PHARMACEUTICAL COMPOSITION CONTAINING A SALT OF THE D ACID; A SALT OF THE D ACID | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1983-06-29 | — | — | EP | claimed |
| EP-0017169-B1 | IMPROVED ANTI-INFLAMMATORY COMBINATIONS HAVING REDUCED ULCEROGENICITY | MERCK & CO. INC. (US) | 1983-03-09 | — | — | EP | claimed |
| EP-0044984-A1 | Process for the optical resolution of mixtures of d- and l-2-(6-methoxy-2-naphthyl)-propionic acids, the cinchonidine salt of d-2-(6-methoxy-2-naphthyl)-propionic acid and the preparation thereof | ALFA FARMACEUTICI S.p.A. (IT) | 1982-02-03 | — | — | EP | claimed |
| US-4279926-A | PHENYL ALKANOIC ACID SALT OF AN AMINO ACID | SPA-SOCIETA PRODOTTI ANTIBIOTICI S.P.A. (IT) | 1981-07-21 | — | — | US | claimed |
| EP-0022529-A1 | Process for the resolution of d,l 2-(6-methoxy-2-naphthyl)propionic acid; a mixture of the salts of these d and l acids; a pharmaceutical composition containing a salt of the d acid; a salt of the d acid | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1981-01-21 | — | — | EP | claimed |
| EP-0017169-A1 | Improved anti-inflammatory combinations having reduced ulcerogenicity | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023208-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE ANTIINFLAMMATORY SUBSTANCE | CCL11, MGLL, LIPA | PTGS2 70/4885PTGS1 19/4885AKR1C3 515/4885 |
| US-20220288022-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE THAT IS IN THE FORM OF A DISPERSED PHASE BASED ON AT LEAST ONE SHORT DIOL IN A CONTINUOUS FATTY PHASE AND COMPRISING AT LEAST ONE ANTI-INFLAMMATORY SUBSTANCE | PTGER1, RAD1, REV1 | PTGS2 566/4885PTGS1 24/4885AKR1C3 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.